

INVESTIGATOR INITIATED STUDY (IIS) APPLICATION

CONTACT DETAILS		
Date of proposal:		
Laboratory/Institute:		
City:		
Country:		
Principal Investigator:	Name: Email address: Phone number:	
Curriculum vitae enclosed?	□ Yes □ No	
Current Idylla™ user?	□ Yes □ No	
Primary Idylla™ user contact details	Name: Email address: Phone number:	
Do you use Idylla™ Explore?	□ Yes □ No	
Is the Idylla [™] System connected?	□ Yes □ No	

STUDY DETAILS			
Project/Study Proposal/ Scientific Abstract			
	See attachment		



			Prospective Retrospecti	ive
		Observational Other		
		□ Single center □ Multi center (sites)		
Aim of the project		Primary objective:		
		Secondary objective:		
Do you plan to publish?		□ Yes □ No		
			Estimated time of submission:	
Product ¹ / labeling ¹		□ APIS B	Breast Cancer Subtyping Kit ^{2,4}	□ NRAS-BRAF-EGFR S492R
	□ IVD	□ APIS ESR1 Mutations Kit ^{2,4}		□ PIK3CA-AKT1
				POLE-POLD1
				☐ ThyroidPrint® ²
		□ ctEGFR		
		□ ctESR1		
		□ ctKRAS		
		CtNRAS-BRAF-EGFR S492R		
		□ EGFR		
		□ GeneFusion		
		HepatoPredict ^{2,4}		
		□ IDH1-2		
		□ MSI		
		□ MSI 51	10(k)	
		□ NRAS-BRAF		

¹In markets where available. ²Biocartis NV is the distributor. ³Idylla™ CP-GEP (Clinicopathological Gene Expression Profiling) Assay. ⁴Not designed to be run on the Idylla™ System.



Sample type	Core needle - tissue (FFPE)
	Resected - tissue (FFPE)
	Cell block - cytological
	□ Smear - cytological
	🗌 Monolayer - cytological
	□ Fresh (non-fixated)
	Plasma
	Blood
	Extracted DNA from tissue
	Extracted DNA from cytological
	Touch Prep
	Urine
	🗆 Saliva
	Nasopharyngeal swabs
	Oropharyngeal swabs
	□ Other, specify:
Disease area:	
Total sample size (number):	
Target patient population:	
Open remark:	
If applicable, Reference technology	
 Examples: NGS; the Ion AmpliSeq Cancer Hot Spot panel v2 (Illumina) NGS; the Oncomine Solid Tumor DNA Kit (ThermoFisher) RT-PCR; the cobas® EGFR Mutation Test v2 (Roche) 	



If applicable, Monitoring test scheme (eg ctDNA) Example of three time points: - Plasma and tissue testing before surgery (baseline) - Plasma testing after surgery 3 months - Plasma testing after surgery 12 months	
If applicable, Clinical Trial number	
If applicable,	EC/IRB approval:
EC/IRB approvals	\Box yes \Box no \Box ongoing \Box not applicable
Informed Consent approvals	
	Informed consent* approval:
	\Box yes \Box no \Box ongoing \Box not applicable
	*capturing data and material

REQUEST FOR MATERIAL NEEDED FOR THE STUDY		
Requested number of Idylla™ cartridges		
Requested number of Idylla™ systems	Idylla™ Console: Idylla™ Instrument:	
Timing (start/end)	Estimation start date: Estimation end date:	
Other Examples: - Publication cost - Support for medical writer - Cost of discordant analysis		

<u>Privacy Notice:</u> Biocartis collects, uses, shares, retains and discloses personal data based on the Biocartis's <u>privacy policy</u>. If you have any questions with regard to the content of this policy, the processing of personal data or the exercise of data subject rights in relation to this data processed by Biocartis, you can contact <u>dpo@biocartis.com</u>.

 \odot December 2024, Biocartis NV. All rights reserved.